TY - JOUR
T1 - The effects of excess weight on glucose homeostasis in young adult females with β-thalassemia major (β-TM)
T2 - A preliminary retrospective study
AU - De Sanctis, Vincenzo
AU - Daar, Shahina
AU - Soliman, Ashraf T.
AU - Tzoulis, Ploutarchos
AU - Yassin, Mohamed
AU - Kattamis, Christos
N1 - Publisher Copyright:
© Mattioli 1885.
PY - 2023
Y1 - 2023
N2 - Background: With the rising prevalence of obesity worldwide, it is becoming imperative to detect disturbed glucose metabolism as early as possible in order to prevent type 2 diabetes (T2D) develop-ment. Study design: The present retrospective observational study aimed to evaluate the relationship between BMI and glucose metabolism, insulin secretion and sensitivity indices, derived from glucose tolerance test (OGTT), in β-TM female patients who were overweight (BMI 25-29.9 kg/m2) and follow its outcome over time. Subjects and Methods: Eleven overweight and 11 females with ideal weight and β-TM, matched for age, were recruited. OGTT was undertaken and different indices for β-cell function, insulin sensitivity and insulin secretion were calculated. Results: At first evaluation, 7 of 11 overweight β-TM patients (63.6%) and 3 of 11 normal weight β-TM patients (27.2%) had glucose dysregulation (GD) during OGTT. Overweight patients with β-TM had increased HOMA-IR and QUICKI indices associated with decreased Matsuda WBISI index. The mean ± SD duration of follow-up was 4.5 ± 1.2 years. At last observation, 2/11 overweight patients had developed T2D (18.1%). In patients with normal weight, GD increased from 3/11 (27.2%) to 5/11 (45.4%), but none developed T2DM. The difference between SF at first and last observation (1,220 ± 702 vs.1,091 ± 454 ng/mL; P: 0.61) was not significant. Conclusion: Overweight seems to be an additional risk factor for the development of GD in β-TM patients. This is particularly important in clinical practice, due to the lack of appropriate guidelines dedicated to this group of patients. (www.actabiomedica.it).
AB - Background: With the rising prevalence of obesity worldwide, it is becoming imperative to detect disturbed glucose metabolism as early as possible in order to prevent type 2 diabetes (T2D) develop-ment. Study design: The present retrospective observational study aimed to evaluate the relationship between BMI and glucose metabolism, insulin secretion and sensitivity indices, derived from glucose tolerance test (OGTT), in β-TM female patients who were overweight (BMI 25-29.9 kg/m2) and follow its outcome over time. Subjects and Methods: Eleven overweight and 11 females with ideal weight and β-TM, matched for age, were recruited. OGTT was undertaken and different indices for β-cell function, insulin sensitivity and insulin secretion were calculated. Results: At first evaluation, 7 of 11 overweight β-TM patients (63.6%) and 3 of 11 normal weight β-TM patients (27.2%) had glucose dysregulation (GD) during OGTT. Overweight patients with β-TM had increased HOMA-IR and QUICKI indices associated with decreased Matsuda WBISI index. The mean ± SD duration of follow-up was 4.5 ± 1.2 years. At last observation, 2/11 overweight patients had developed T2D (18.1%). In patients with normal weight, GD increased from 3/11 (27.2%) to 5/11 (45.4%), but none developed T2DM. The difference between SF at first and last observation (1,220 ± 702 vs.1,091 ± 454 ng/mL; P: 0.61) was not significant. Conclusion: Overweight seems to be an additional risk factor for the development of GD in β-TM patients. This is particularly important in clinical practice, due to the lack of appropriate guidelines dedicated to this group of patients. (www.actabiomedica.it).
KW - excess weight
KW - glucose homeostasis
KW - insulin secretion and sensitivity
KW - oral glucose tolerance test
KW - β-thalassemia major
UR - http://www.scopus.com/inward/record.url?scp=85174750399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174750399&partnerID=8YFLogxK
U2 - 10.23750/abm.v94i6.14909
DO - 10.23750/abm.v94i6.14909
M3 - Article
C2 - 37850764
AN - SCOPUS:85174750399
SN - 0392-4203
VL - 94
JO - Acta Biomedica
JF - Acta Biomedica
IS - 5
M1 - e2023225
ER -